Concurrent Investment Advisors LLC Has $2.41 Million Stock Holdings in Zoetis Inc. (NYSE:ZTS)

Concurrent Investment Advisors LLC boosted its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 52.6% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 14,765 shares of the company’s stock after acquiring an additional 5,091 shares during the period. Concurrent Investment Advisors LLC’s holdings in Zoetis were worth $2,406,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of ZTS. Mizuho Securities USA LLC grew its holdings in Zoetis by 13,726.9% during the 3rd quarter. Mizuho Securities USA LLC now owns 4,865,000 shares of the company’s stock worth $950,524,000 after acquiring an additional 4,829,815 shares during the period. International Assets Investment Management LLC grew its holdings in shares of Zoetis by 41,235.7% in the 3rd quarter. International Assets Investment Management LLC now owns 939,974 shares of the company’s stock valued at $183,652,000 after buying an additional 937,700 shares during the period. Assenagon Asset Management S.A. grew its holdings in shares of Zoetis by 296.9% in the 4th quarter. Assenagon Asset Management S.A. now owns 889,444 shares of the company’s stock valued at $144,917,000 after buying an additional 665,331 shares during the period. Nordea Investment Management AB grew its holdings in shares of Zoetis by 38.3% in the 4th quarter. Nordea Investment Management AB now owns 2,065,514 shares of the company’s stock valued at $336,266,000 after buying an additional 572,511 shares during the period. Finally, Holocene Advisors LP acquired a new position in shares of Zoetis in the 3rd quarter valued at $110,809,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Trading Up 1.9 %

Shares of NYSE:ZTS opened at $160.39 on Friday. The company’s 50-day moving average price is $166.51 and its two-hundred day moving average price is $178.04. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08. Zoetis Inc. has a one year low of $144.80 and a one year high of $200.53. The stock has a market capitalization of $71.82 billion, a PE ratio of 29.32, a price-to-earnings-growth ratio of 2.77 and a beta of 0.90.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, February 13th. The company reported $1.40 EPS for the quarter, topping the consensus estimate of $1.37 by $0.03. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The firm had revenue of $2.32 billion for the quarter, compared to analysts’ expectations of $2.30 billion. On average, equities analysts forecast that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be given a dividend of $0.50 per share. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 annualized dividend and a yield of 1.25%. Zoetis’s dividend payout ratio (DPR) is presently 36.56%.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the stock. Leerink Partnrs raised shares of Zoetis to a “strong-buy” rating in a report on Monday, December 2nd. Stifel Nicolaus decreased their price target on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. Leerink Partners assumed coverage on shares of Zoetis in a report on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price target for the company. Morgan Stanley reduced their target price on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a research note on Friday, February 14th. Finally, Piper Sandler reduced their target price on shares of Zoetis from $210.00 to $200.00 and set an “overweight” rating for the company in a research note on Monday, February 10th. One analyst has rated the stock with a hold rating, nine have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Zoetis presently has an average rating of “Buy” and an average target price of $214.90.

Insiders Place Their Bets

In other news, EVP Roxanne Lagano sold 326 shares of the company’s stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total value of $55,804.68. Following the sale, the executive vice president now directly owns 16,107 shares of the company’s stock, valued at approximately $2,757,196.26. This represents a 1.98 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.16% of the company’s stock.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.